Attached files
| file | filename |
|---|---|
| EX-10.31 - AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT, DATED JUNE 11, 2018, BETWEEN A - AYTU BIOPHARMA, INC | f10k2018ex10-31_aytubio.htm |
| EX-32.1 - CERTIFICATION - AYTU BIOPHARMA, INC | f10k2018ex32-1_aytubio.htm |
| EX-31.2 - CERTIFICATION - AYTU BIOPHARMA, INC | f10k2018ex31-2_aytubio.htm |
| EX-31.1 - CERTIFICATION - AYTU BIOPHARMA, INC | f10k2018ex31-1_aytubio.htm |
| EX-10.11 - VOTING AGREEMENT BETWEEN THE REGISTRANT AND AMPIO, DATED APRIL 21, 2015 - AYTU BIOPHARMA, INC | f10k2018ex10-11_aytubio.htm |
| EX-10.4 - LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN THE REGISTRANT (AS - AYTU BIOPHARMA, INC | f10k2018ex10-4_aytubio.htm |
| 10-K - ANNUAL REPORT - AYTU BIOPHARMA, INC | f10k2018_aytubioscience.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Aytu BioScience, Inc.’s Registration Statements on Form S-8 (File No. 333-205462), Form S-3 (File No. 333-221735) and Form S-1 (File Nos. 333-207421, 333-205414, 333-209874, 333-210144, 333-212100, 333-213738, 333-213489, 333-220351, 333-222994, and 333-223385) of our report dated September 6, 2018, relating to the consolidated financial statements that appear in this Annual Report on Form 10-K.
Our report dated September 6, 2018 contains an explanatory paragraph that states that the Company's recurring losses from operations and accumulated deficit raise substantial doubt about the Company's ability to continue as a going concern, as discussed in Note 3 to the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.
| /s/ EKS&H LLLP |
| September 6, 2018 |
| Denver, Colorado |